Bisphosphonate Therapy for Reduced Bone Mineral Density in Children with Chronic Graft-versus-Host Disease Paul A. Carpenter, Paul Hoffmeister, Charles.

Slides:

Advertisements

Similar presentations

Stephanie J. Lee, Loretta A. Williams

Advertisements

Sirolimus in Combination with Cyclosporine or Tacrolimus Plus Methotrexate for Prevention of Graft-versus-Host Disease following Hematopoietic Cell Transplantation.

Clinical Evaluation of Oral Chronic Graft-Versus-Host Disease

Accelerated Bone Mineral Density Loss Occurs with Similar Incidence and Severity, But with Different Risk Factors, after Autologous versus Allogeneic.

In Stem Cell Transplantation by Limiting the Morbidity of Graft-versus-Host Disease Tolerance to Myeloablative Conditioning is Improved Nicolas Novitzky,

How to Treat MDS without Stem Cell Transplantation

Increased Cardiometabolic Traits in Pediatric Survivors of Acute Lymphoblastic Leukemia Treated with Total Body Irradiation Eric J. Chow, Jill H. Simmons,

Incidence and Prognostic Value of Eosinophilia in Chronic Graft-versus-Host Disease after Nonmyeloablative Hematopoietic Cell Transplantation Imran Ahmad,

Vaccination of Children following Allogeneic Stem Cell Transplantation

Pharmacokinetics of Ganciclovir after Oral Valganciclovir versus Intravenous Ganciclovir in Allogeneic Stem Cell Transplant Patients with Graft-versus-Host.

Peter Hurley, Suma Konety, Qing Cao, Daniel Weisdorf, Anne Blaes

Sympathectomy Protects Denervated Skin from Graft-Versus-Host Disease

Therapy of Sclerodermatous Chronic Graft-Versus-Host Disease with Mammalian Target of Rapamycin Inhibitors Zuzana Jedlickova, Irina Burlakova, Gesine.

Busulfan, Fludarabine, and Alemtuzumab As a Reduced Toxicity Regimen for Children with Malignant and Nonmalignant Diseases Improves Engraftment and Graft-versus-

Dasatinib as Salvage Therapy for Steroid Refractory and Imatinib Resistant or Intolerant Sclerotic Chronic Graft-versus-Host Disease Isabel Sánchez-Ortega,

Implementation of Post-Transplant Assessment Tools for Improved Accuracy of Graft- Versus-Host Disease Reporting Madhu Ragupathi, Jaskiran Kaur, Luda.

Oral Manifestations Compatible with Chronic Graft-versus-Host Disease in Patients with Fanconi Anemia Laura Grein Cavalcanti, Renata L. Fuentes Araújo,

Sabina Kersting, Leo F. Verdonck

Randomized trial of allogeneic related bone marrow transplantation versus peripheral blood stem cell transplantation for chronic myeloid leukemia Vivian.

Musculoskeletal, Neurologic, and Cardiopulmonary Aspects of Physical Rehabilitation in Patients with Chronic Graft-versus-Host Disease Sean Robinson.

Carbon Monoxide Diffusion Capacity: How Low Can You Go for Hematopoietic Cell Transplantation Eligibility? Jason W. Chien, Keith M. Sullivan Biology.

Stephanie J. Lee, Loretta A. Williams

Late Effects after Umbilical Cord Blood Transplantation in Very Young Children after Busulfan-Based, Myeloablative Conditioning Heather Allewelt, Jill.

Impact of Ocular Chronic Graft-versus-Host Disease on Quality of Life

Re: Twenty-Year Follow-Up in Patients with Aplastic Anemia Given Marrow Grafts from HLA-Identical Siblings and Randomized to Receive Methotrexate/Cyclosporine.

Clinical Benefit of Response in Chronic Graft-versus-Host Disease

Comparison of Short-Term Response and Long-Term Outcomes after Initial Systemic Treatment of Chronic Graft-Versus-Host Disease Paul J. Martin, Barry.

Recent Decrease in Acute Graft-versus-Host Disease in Children with Leukemia Receiving Unrelated Donor Bone Marrow Transplants Stella M. Davies, Dan.

Cytomegalovirus Infection after Allogeneic Transplantation: Comparison of Cord Blood with Peripheral Blood and Marrow Graft Sources Christopher M. Walker,

Ofatumumab in Combination with Glucocorticoids for Primary Therapy of Chronic Graft- versus-Host Disease: Phase I Trial Results Joseph Pidala, Jongphil.

Late-Onset Colitis after Cord Blood Transplantation Is Consistent with Graft-Versus-Host Disease: Results of a Blinded Histopathological Review Filippo.

Helicobacter pylori Infection and Graft-versus-Host Disease

Oral Chronic Graft-versus-Host Disease Scoring Using the NIH Consensus Criteria Nathaniel S. Treister, Kristen Stevenson, MS, Haesook Kim, Sook-Bin Woo,

Dysglycemia Following Glucocorticoid Therapy for Acute Graft-versus-Host Disease Adversely Affects Transplantation Outcomes Joseph Pidala, Jongphil Kim,

A Novel Strategy in Managing Post-Liver Transplant Acute Graft-Versus-Host-Disease: The New Era (T)Rojan Horse Zeyad Kanaan, MD, William Tse, MD, FACP

Paul A. Hoffmeister, Sangeeta R. Hingorani, Barry E. Storer, K

Betty K. Hamilton, Lisa Rybicki, Sally Arai, Mukta Arora, Corey S

Paul J. Martin, Terry Furlong, Scott D. Rowley, Steven A

A Novel Soluble Form of Tim-3 Associated with Severe Graft-versus-Host Disease John A. Hansen, Samir M. Hanash, Laura Tabellini, Chris Baik, Richard L.

Iron Overload Manifesting as Apparent Exacerbation of Hepatic Graft-versus-Host Disease after Allogeneic Hematopoietic Stem Cell Transplantation Rammurti.

Sabina Kersting, Ronald J. Hené, Hein A. Koomans, Leo F. Verdonck

Response of Steroid-Refractory Acute GVHD to α1-Antitrypsin

Outcomes of Cord Blood Transplantation as Salvage Therapy after Graft Failure or Relapse after Prior Allogeneic Transplantation Rachel B. Salit, Filippo.

Regression Models for Hazard Rates Versus Cumulative Incidence Probabilities in Hematopoietic Cell Transplantation Data Brent R. Logan, Mei-Jie Zhang,

Mohammad Alhyari, M. D. , Aymen Bukannan, M. D. , Kimberly Brown, M. D

Anna Petryk, Lynda E. Polgreen, Jessie L. Barnum, Lei Zhang, James S

Tbo-Filgrastim versus Filgrastim during Mobilization and Neutrophil Engraftment for Autologous Stem Cell Transplantation Mohammed M. Elayan, Justin G.

Reduced Incidence of Acute and Chronic Graft-versus-Host Disease with the Addition of Thymoglobulin to a Targeted Busulfan/Cyclophosphamide Regimen H.

Content Validity of the Lee Chronic Graft-versus-Host Disease Symptom Scale as Assessed by Cognitive Interviews Emily C. Merkel, Sandra A. Mitchell,

Heterogeneity in Studies of Mesenchymal Stromal Cells to Treat or Prevent Graft- versus-Host Disease: A Scoping Review of the Evidence Mina Rizk, Madeline.

Unrelated Stem Cell Transplantation after a Reduced Intensity Conditioning Regimen Containing High-Dose Thymoglobulin Leads to Controllable Graft-versus-Host.

John E. Levine, Sophie Paczesny, Stefanie Sarantopoulos

HLA-Allele Matched Unrelated Donors Compared to HLA-Matched Sibling Donors: Role of Cell Source and Disease Risk Category Ann Woolfrey, Stephanie J.

Biology of Blood and Marrow Transplantation

Allogeneic Hematopoietic Stem Cell Transplantation in FLT3-ITD–Positive Acute Myelogenous Leukemia: The Role for FLT3 Tyrosine Kinase Inhibitors Post-

Blood and Marrow Transplant Handbook

Young Female Donors Do Not Increase the Risk of Graft-versus-Host Disease or Impact Overall Outcomes in Pediatric HLA-Matched Sibling Hematopoietic Stem.

Preengraftment Syndrome after Unrelated Cord Blood Transplant Is a Strong Predictor of Acute and Chronic Graft-versus-Host Disease Haydar Frangoul, Li.

Low Serum Levels of Total Rabbit-IgG Is Associated with Acute Graft-Versus-Host Disease after Unrelated Donor Hematopoietic Stem Cell Transplantation:

Alveolar Hemorrhage and Acute Graft-versus-Host Disease

Mammen Chandy Biology of Blood and Marrow Transplantation

Yuri Fedoriw, T. Danielle Samulski, Allison M. Deal, Cherie H

Treatment versus Transplant for Challenging Hematologic Disorders

Prospective Monitoring of Tumor Necrosis Factor α and Interferon γ to Predict the Onset of Acute and Chronic Graft-versus-Host Disease after Allogeneic.

Outcomes among Patients with Recurrent High-Risk Hematologic Malignancies after Allogeneic Hematopoietic Cell Transplantation Marco Mielcarek, Barry.

Mary Eapen Biology of Blood and Marrow Transplantation

In Memoriam: E. Donnall Thomas

Daniel Couriel, Chitra Hosing, Rima Saliba, Elizabeth J

Infliximab for Managing Steroid-Refractory Acute Graft-versus-Host Disease Joseph Pidala, Jongphil Kim, Teresa Field, Ali McBride, Mohamed Kharfan-Dabaja,

Andrew R. Rezvani, Barry E. Storer, Katherine A. Guthrie, H

Presentation transcript:

Bisphosphonate Therapy for Reduced Bone Mineral Density in Children with Chronic Graft-versus-Host Disease Paul A. Carpenter, Paul Hoffmeister, Charles H. Chesnut, Barry Storer, Paula M. Charuhas, Ann E. Woolfrey, Jean E. Sanders Biology of Blood and Marrow Transplantation Volume 13, Issue 6, Pages 683-690 (June 2007) DOI: 10.1016/j.bbmt.2007.02.001 Copyright © 2007 American Society for Blood and Marrow Transplantation Terms and Conditions

Figure 1 Bone mineral density at baseline and after follow-up. Shown for the patients treated without (n = 48) and with (n = 18) bisphosphonates are: (A) the standardized BMD (sBMD) for each patient, together with the median sBMD (filled large squares), at baseline (pre) and at follow-up (post), and (B) the median, 25th, and 75th percentiles (box), and range of the rates of change of sBMD (whiskers). Biology of Blood and Marrow Transplantation 2007 13, 683-690DOI: (10.1016/j.bbmt.2007.02.001) Copyright © 2007 American Society for Blood and Marrow Transplantation Terms and Conditions

Figure 2 Annualized bone mineral density at baseline and after follow-up. Shown for the patients treated without (n = 48) and with (n = 18) bisphosphonates are: (A) the BMD Z-scores for each patient, together with the median Z-score (filled large squares), at baseline (pre) and at follow-up (post), and (B) the median, 25th, and 75th percentiles (box), and range of the rates of change of Z-scores (whiskers). Biology of Blood and Marrow Transplantation 2007 13, 683-690DOI: (10.1016/j.bbmt.2007.02.001) Copyright © 2007 American Society for Blood and Marrow Transplantation Terms and Conditions